AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today ...

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in ...

AbbVie and Gubra ink license agreement to develop an amylin analog for the treatment of obesity: North Chicago, Illinois Tuesday, March 4, 2025, 10:00 Hrs [IST] AbbVie and Gubra A ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, ...

BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...

AbbVie and Gubra have partnered to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

In a partnership marking AbbVie’s entrance into the weight management field, the US pharma major has signed a licensing deal ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Yahoo Finance host Josh Lipton tracks the day's biggest stocks in this Market Minute. AbbVie (ABBV) announced a licensing ...